RxSight, Inc. is a medical technology company that develops and commercializes the Light Adjustable Lens (LAL) system, an FDA-approved customizable intraocular lens for cataract surgery patients that allows surgeons to adjust lens power after surgery rather than before, eliminating pre-operative guesswork about patient vision preferences. The company operates a "razor and razor blade" business model in which customers purchase the Light Delivery Device and enter into lens supply agreements, with surgeons implanting the LAL during standard cataract surgery and using office-based equipment for post-operative adjustments, while patients pay out-of-pocket premiums beyond standard Medicare coverage. RxSight targets high-volume cataract surgeons in the U.S. premium IOL market, which represents a significant portion of the broader cataract surgery market, and has regulatory approval in multiple geographies with current commercial emphasis on the United States.